Talita Morais Fernandes

Dr. Talita Morais Fernandes

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
Pedro Vieira da Silva NetoPedro Vieira da Silva Neto
Pedro Vieira da Silva Neto
VVValéria Beatriz do Valle
Valéria Beatriz do Valle
CFCarlos Fuzo
Carlos Fuzo
TFTalita Morais Fernandes
Talita Morais Fernandes
DTDiana Mota Toro
Diana Mota Toro
OGon behalf of the IMMUNOCOVID Study Group
on behalf of the IMMUNOCOVID Study Group
Patients with COVID-19 predominantly have a respiratory tract infection and acute lung failure is the most severe complication. While the molecular basis of SARS-CoV-2 immunopathology is still unknown, it is well established that lung infection is associated with hyper-inflammation and tissue damage. Matrix metalloproteinases (MMPs) contribute to tissue destruction in many pathological situations, and the activity of MMPs in the lung leads to the release of bioactive mediators with inflammatory properties. We sought to characterize a scenario in which MMPs could influence the lung pathogenesis of COVID-19. Although we observed high diversity of MMPs in lung tissue from COVID-19 patients by proteomics, we specified the expression and enzyme activity of MMP-2 in tracheal-aspirate fluid (TAF) samples from intubated COVID-19 and non-COVID-19 patients. Moreover, the expression of MMP-8 was positively correlated with MMP-2 levels and possible shedding of the immunosuppression mediator sHLA-G and sTREM-1. Together, overexpression of the MMP-2/MMP-8 axis, in addition to neutrophil infiltration and products, such as reactive oxygen species (ROS), increased lipid peroxidation that could promote intensive destruction of lung tissue in severe COVID-19. Thus, the inhibition of MMPs can be a novel target and promising treatment strategy in severe COVID-19.

15 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Pedro Vieira da Silva NetoPedro Vieira da Silva Neto
Pedro Vieira da Silva Neto
Jonatan Constança Silva de CarvalhoJonatan Constança Silva de Carvalho
Jonatan Constança Silva de Carvalho
Vinícius Eduardo PimentelVinícius Eduardo Pimentel
Vinícius Eduardo Pimentel
MPMalena M. Pérez
Malena M. Pérez
DTDiana Mota Toro
Diana Mota Toro
OGon behalf of the IMUNOCOVID Study Group
on behalf of the IMUNOCOVID Study Group
Uncontrolled inflammatory responses play a critical role in coronavirus disease (COVID-19). In this context, because the triggering-receptor expressed on myeloid cells-1 (TREM-1) is considered an intrinsic amplifier of inflammatory signals, this study investigated the role of soluble TREM-1 (sTREM-1) as a biomarker of the severity and mortality of COVID-19. Based on their clinical scores, we enrolled COVID-19 positive patients (n = 237) classified into mild, moderate, severe, and critical groups. Clinical data and patient characteristics were obtained from medical records, and their plasma inflammatory mediator profiles were evaluated with immunoassays. Plasma levels of sTREM-1 were significantly higher among patients with severe disease compared to all other groups. Additionally, levels of sTREM-1 showed a significant positive correlation with other inflammatory parameters, such as IL-6, IL-10, IL-8, and neutrophil counts, and a significant negative correlation was observed with lymphocyte counts. Most interestingly, sTREM-1 was found to be a strong predictive biomarker of the severity of COVID-19 and was related to the worst outcome and death. Systemic levels of sTREM-1 were significantly correlated with the expression of matrix metalloproteinases (MMP)-8, which can release TREM-1 from the surface of peripheral blood cells. Our findings indicated that quantification of sTREM-1 could be used as a predictive tool for disease outcome, thus improving the timing of clinical and pharmacological interventions in patients with COVID-19.

Verified
Journal Article
Open access
PDF file
JCJéssica Fernanda Corrêa Cordeiro
Jéssica Fernanda Corrêa Cordeiro
TFTalita Morais Fernandes
Talita Morais Fernandes
DTDiana Mota Toro
Diana Mota Toro
Pedro Vieira da Silva NetoPedro Vieira da Silva Neto
Pedro Vieira da Silva Neto
Vinícius Eduardo PimentelVinícius Eduardo Pimentel
Vinícius Eduardo Pimentel
OGon behalf of the IMMUNOCOVID Study Group
on behalf of the IMMUNOCOVID Study Group
The non-classical histocompatibility antigen G (HLA-G) is an immune checkpoint molecule that has been implicated in viral disorders. We evaluated the plasma soluble HLA-G (sHLA-G) in 239 individuals, arranged in COVID-19 patients (n = 189) followed up at home or in a hospital, and in healthy controls (n = 50). Increased levels of sHLA-G were observed in COVID-19 patients irrespective of the facility care, gender, age, and the presence of comorbidities. Compared with controls, the sHLA-G levels increased as far as disease severity progressed; however, the levels decreased in critically ill patients, suggesting an immune exhaustion phenomenon. Notably, sHLA-G exhibited a positive correlation with other mediators currently observed in the acute phase of the disease, including IL-6, IL-8 and IL-10. Although sHLA-G levels may be associated with an acute biomarker of COVID-19, the increased levels alone were not associated with disease severity or mortality due to COVID-19. Whether the SARS-CoV-2 per se or the innate/adaptive immune response against the virus is responsible for the increased levels of sHLA-G are questions that need to be further addressed.

8 July 2025 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
Alvaro Francisco Lopes de SousaAlvaro Francisco Lopes de Sousa
Alvaro Francisco Lopes de Sousa
Caíque Jordan Nunes RibeiroCaíque Jordan Nunes Ribeiro
Caíque Jordan Nunes Ribeiro
GSGuilherme Reis de Santana Santos
Guilherme Reis de Santana Santos
Emerson Lucas Silva CamargoEmerson Lucas Silva Camargo
Emerson Lucas Silva Camargo
Herica Emilia Félix de CarvalhoHerica Emilia Félix de Carvalho
Herica Emilia Félix de Carvalho
IMIsabel Amelia Costa Mendes
Isabel Amelia Costa Mendes
Background: In Brazil, men who have sex with men (MSM) are disproportionately affected by the HIV epidemic, mirroring global trends. Despite advancements in HIV prevention, such as pre-exposure prophylaxis (PrEP), uptake remains uneven among different MSM age groups, influenced by various sexual behaviors, risk perceptions, and social stigmas. Objective: This study aimed to investigate factors associated with PrEP intentions among Brazilian MSM across different age groups. Methods: A cross-sectional electronic survey was conducted with Brazilian MSM aged 18 years and above. Results: PrEP intentions were expressed by 55.1% (2390/4341) of participants. Among those under 25 years old, frequent barebacking was associated with a 25.4-fold higher prevalence of PrEP intentions (95% CI 18.18‐35.48). Conversely, having one or more casual sexual partners in the last 30 days (2164/3838) was associated with a 22% lower frequency of PrEP intentions (95% CI 0.72‐0.85). The practice of chemsex was also associated with a lower prevalence of PrEP intentions (adjusted prevalence ratio [aPR] 0.96; 95% CI 0.94‐0.98). Among individuals aged 25‐49 years, the practice of double penetration was associated with a higher prevalence of PrEP intentions (aPR 1.22; 95% CI .13‐1.32), as was being a receptive or versatile partner (aPR 1.27; 95% CI 1.04‐1.55 and aPR 1.23; 95% CI 1.01‐1.49). In addition, within this age range, a higher prevalence of PrEP intentions (over 10% 258/429]) was found among those with specific characteristics, such as a previous diagnosis of syphilis (aPR 1.12; 95% CI 1.03‐1.22). However, being single (aPR 0.90; 95% CI 0.83‐0.97) and having a partner who used PrEP (aPR 0.82; 95% CI 0.72‐0.93) were associated with a lower prevalence of PrEP intentions. For MSM aged ≥50 years, a higher prevalence of PrEP intentions was associated with the practice of double penetration (aPR 1.31; 95% CI 1.20‐1.43), as well as being a receptive (aPR 1.27; 95% CI 1.04‐1.55) or versatile partner (aPR 1.23; 95% CI 1.01‐1.50). The practice of group sex was independently associated with a lower prevalence of PrEP intentions exclusively among MSM aged ≥50 years (aPR 0.82; 95% CI 0.75‐0.89). Conclusions: The study highlights significant generational differences in factors influencing PrEP intentions among Brazilian MSM. It underscores the need for tailored HIV prevention strategies that consider the unique behaviors and perceptions of different age groups. By addressing these nuances, public health initiatives can more effectively promote PrEP use, catering to the diverse needs of the MSM community and contributing to the reduction of HIV infection rates.

9 November 2024 in Journal of Bodywork and Movement Therapies
Verified
Journal Article
Closed access
WSWlaldemir Roberto dos Santos
Wlaldemir Roberto dos Santos
WSWalmir Romário dos Santos
Walmir Romário dos Santos
PPPedro Pinheiro Paes
Pedro Pinheiro Paes
TFTalita Morais Fernandes
Talita Morais Fernandes
TFTalita Morais Fernandes
Talita Morais Fernandes

26 March 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
LCLariane Angel Cepas
Lariane Angel Cepas
ICIsadora Silva de Carvalho
Isadora Silva de Carvalho
Alvaro Francisco Lopes de SousaAlvaro Francisco Lopes de Sousa
Alvaro Francisco Lopes de Sousa
Caíque Jordan Nunes RibeiroCaíque Jordan Nunes Ribeiro
Caíque Jordan Nunes Ribeiro
SLShirley Veronica Melo Almeida Lima
Shirley Veronica Melo Almeida Lima
AFAna Paula Morais Fernandes
Ana Paula Morais Fernandes
Background: Chemsex, defined as the intentional use of psychoactive substances to enhance sexual experiences, is associated with increased risk of sexually transmitted infections (STIs), mental health harms, and disruptions in continuity of care, particularly among men who have sex with men. In Brazil, health services lack an integrated, stigma-sensitive care pathway (CP) for prevention, clinical management, and harm reduction. Embedding a CP within the Health Care Network (HCN) is essential to organize access, continuity, and quality of care. Objective: This study aims to develop an evidence-informed CP for people who engage in chemsex, grounded in the needs of users, managers, and health professionals within the HCN, and supported by educational tools and implementation strategies. Methods: This sequential multimethod study is guided by the Knowledge-to-Action framework. Phase 1 (predevelopment) focuses on establishing partnerships and mapping the local context. Phase 2 (Knowledge Creation) includes (1) cross-sectional surveys with adults from the general population (target n≈1600) to estimate chemsex prevalence and associated factors, and with managers (n≈54) and health professionals (n≈135) to assess knowledge, attitudes, practices, barriers, and stigma; (2) a scoping review following established methodological guidelines; and (3) triangulation and concept mapping to integrate quantitative and qualitative findings. Data will be collected via REDCap (Research Electronic Data Capture), online and in person, during testing events. Quantitative analyses will involve descriptive statistics and regression models. Interviews and focus groups will undergo thematic analysis supported by Nvivo software. Educational products will be developed and evaluated for appearance, content, and usability by experts using a content validity index ≥0.78 as a cutoff. Phase 3 (Action Cycle) includes adapting knowledge to the local context, co-designing and validating the CP with stakeholders, piloting implementation in priority municipalities, and establishing monitoring processes. Process indicators (eg, number of trained professionals, educational activities, rapid tests performed, and app engagement) and outcome indicators (eg, STI testing and linkage to care, service use across the HCN) will be monitored through official information systems. Results: Ethical approval was obtained in April 2025. Recruitment and data collection began in June 2025 through online and in-person strategies. By December 2025, 3061 individuals had been screened online, and 1723 participants had undergone rapid testing for STIs. Data collection is expected to conclude by June 2026, followed by data cleaning and preliminary analyses between April and June 2026, inferential and qualitative analyses between July and September 2026, and CP development and validation between October and December 2026. Conclusions: This protocol will generate a CP tailored to chemsex and validated educational resources to support harm reduction, mental health, and STI prevention within the HCN. Findings are expected to inform inclusive policies, reduce stigma, and strengthen care coordination within Brazil’s Unified Health System. International Registered Report Identifier (IRRID): DERR1-10.2196/84068